259 results on '"Quelle, Dawn E."'
Search Results
2. Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice
3. Functional Copy-Number Alterations as Diagnostic and Prognostic Biomarkers in Neuroendocrine Tumors.
4. NF1+/ex42del miniswine model the cellular disruptions and behavioral presentations of NF1‐associated cognitive and motor impairment.
5. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis
6. FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy
7. Supplementary Figure S4 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
8. Supplementary Table S1 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
9. Data from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
10. FOXM1, MEK, and CDK4/6: New targets for MPNST therapy
11. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth
12. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
13. Longitudinal phenotype development in a minipig model of neurofibromatosis type 1
14. Assessment of nociception and related quality of life measures in a porcine model of Neurofibromatosis type 1
15. Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth in vivo
16. Data from The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis
17. Supplementary Figure 1 from The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis
18. Supplementary table 2 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
19. Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
20. Supplementary Data Figures from RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors
21. Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
22. Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
23. Supplementary table 4 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
24. Supplementary table 3 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
25. Data from RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner
26. Figure S4 from RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner
27. Table S1 from RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner
28. Supplementary Tables S1 & S2 from Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues
29. Cancer-Associated Mutations at the INK4a Locus Cancel Cell Cycle Arrest by p16INK4a but not by the Alternative Reading Frame Protein p19ARF
30. Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growthin vivo
31. Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
32. Preclinical Models of Neuroendocrine Neoplasia
33. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
34. Control of G1 Progression by Mammalian D-Type Cyclins
35. Development and translational imaging of a TP53 porcine tumorigenesis model
36. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets
37. Localized Cytosolic Domains of the Erythropoietin Receptor Regulate Growth Signaling and Down-Modulate Responsiveness to Granulocyte-Macrophage Colony Colony-Stimulating Factor
38. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
39. RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo
40. RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner
41. Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
42. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling
43. Pdgfrα-Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis
44. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors
45. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
46. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
47. Validating indicators of CNS disorders in a swine model of neurological disease
48. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities
49. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging
50. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.